Novaled Ag

Synbias Pharma Ag

Other

Aicuris Anti-infective Cures Gmbh

Arevipharma Gmbh

Novaled Gmbh

Schickaneder, Helmut

Schickaneder, Christian

Michael Limmert

Horst Hartmann

Andrea Lux

Wilfried Schwab

Carsten Rothe

Helmut Schickaneder

Jan Birnstock

Ansgar Werner

Olaf Zeika

Sascha Dorok

Christian Schickaneder

Armin Buschauer

Stefan Huber

Harald Hofmeier

Martin Ammann

Andre Gruessing

Günther Bernhardt

Mathias Lubbe

Steffen Willmann

Kentaro Harada

Mathias Berwe

Sven Murano

Martin Vehse

Clemens Bothe

Helge Hartenhauer

Guenther Bernhardt

Dirk Jung

Welljanne Martens

Nicole Rindermann

Martin Amman

Heike Heydemüller

Olaf Kühl

Simon Gessler

Andre Grüssing

Gunther Bernhardt

Welljanne MÄRTENS

André Grüssing

André Grüßing

Andre c/o Novaled Gmbh Grüssing

The present invention relates to bendamustine derivatives and related compounds of formula (VII), (VIII) and (IX), and medical uses thereof in particular in cancer therapy. 

Bendamustine derivatives and related compounds, and medical use thereof in cancer therapy

The present invention provides for amorphous Letermovir and orally administrable solid pharmaceutical formulations thereof (immediate release formulation). Said amorphous Letermovir is suitable for immediate release formulations when isolated out of an organic solution by either roller-drying said organic solution in a volatile organic solvent, in particular acetone, at a temperature of 30&#xb0; C. to 60&#xb0; C., and subsequently drying the amorphous Letermovir obtained, or isolating said amorphous Letermovir by precipitation from water miscible solvents selected from acetone or acetonitrile into excess water as anti-solvent, and subsequently filtrating or centrifuging the amorphous Letermovir obtained. The immediate release formulations of amorphous Letermovir are intended for use in methods of prophylaxis or methods of treatment of diseases associated with the group of Herpesviridae, preferably associated with cytomegalovirus (CMV), even more preferably associated with human cytomegalovirus (HCMV).

Amorphous letermovir and solid pharmaceutical formulations thereof for oral administration

The invention relates to aryl- and/or heteroaryl-substituted main group element halides and/or pseudohalides, the use of main group element halides and/or pseudohalides as dopant for the doping of an organic semiconducting matrix material, as charge injection layer, as hole blocker layer, as electrode material, as transport material itself, as memory material in electronic or optoelectronic structural elements.

Aryl-substituted and/or heteroaryl-substituted main group element halides and/or pseudohalides, use of main group element halides and/or pseudohalides, organic semiconducting matrix material, electronic and optoelectronic components

The present invention relates to heterocyclic radicals or diradicals, the dimers, oligomers, polymers, dispiro compounds and polycycles thereof, to the use thereof, to organic semiconductive materials and to electronic and optoelectronic components.

Heterocyclic radical or diradical, the dimers, oligomers, polymers, dispiro compounds and polycycles thereof, the use thereof, organic semiconductive material and electronic or optoelectronic component

The present invention relates to a method for preparing doped organic semiconductor materials as well as a formulation which may be utilized in that method. The doped organic semiconductor materials are prepared by preparing a solution or suspension containing at least one dopant precursor, at least one organic material to be doped, and a solvent. The solution or suspension is then applied onto a substrate. After removing the solvent, the dopant precursor is converted into a dopant by application of activation energy. The dopant precursor, which is a dimer, oligomer, polymer, dispiro compound, or polycycle, is cleaved by the application of activation energy.

Method for preparing doped organic semiconductor materials and formulation utilized therein

4,6-dichloro-2-methyl-5-(1-acyl-2-imidazolin-2-yl)-aminopyrimidine is reacted with methanol in the presence of a non-ionic organic base, and moxonidine is obtained directly from the reaction mixture.

Process for the production of moxonidine

Use of a precursor of an n-dopant for doping an organic semiconductive material, as a blocking layer, as a charge injection layer, as an electrode material, as a storage material or as a semiconductor material itself in electronic or optoelectronic components, the precursor being selected from the following formulae 1-3c: 

Use of a precursor of an N-dopant for doping an organic semiconductive material, precursor and electronic or optoelectronic component

The present invention relates to particular esters of bendamustine and related compounds, and medical uses thereof.

Esters of bendamustine and related compounds, and medical use thereof

The present invention relates to the use of heterocyclic radicals or diradicals, their dimers, oligomers, polymers, dispiro compounds and polycycles for use as dopant for doping an organic semiconductive matrix material, where the dopants have a structure based on the following formulae. 

Use of heterocyclic radicals for doping organic semiconductors

A method of using a metal complex as an n-dopant for doping an organic semiconducting matrix material in order to alter the latter's electrical characteristics is provided. In order to provide n-doped organic semiconductors with matrix materials having a low reduction potential, while achieving high conductivities, the n-dopant is a neutral electron-rich metal complex with a neutral or charged transition metal atom as a central atom and having at least 16 valence electrons. The complex can be polynuclear and can possess at least one metal-metal bond. At least one ligand can form a &#x3c0; complex with the central atom, which can be a bridge ligand, or it can contain at least one carbanion-carbon atom or a divalent atom. Methods for providing the novel n-dopants are provided.

Use of a metal complex as an n-Dopant for an organic semiconducting matrix material, organic of semiconducting material and electronic component, and also a dopant and ligand and process for producing same

The present invention relates to heterocyclic radicals or diradicals, the dimers, oligomers, polymers, dispiro compounds and polycycles thereof, to the use thereof to organic semiconductive materials and to electronic and optoelectronic components.

Growing community of inventors

Dresden, Germany

Michael Limmert